Patient-Reported Outcomes with Ibrutinib-Rituximab in WM: Results from iNNOVATE

Conference Correspondent - ASCO 2019 - Chronic Lymphocytic Leukemia

Patients with Waldenström’s macroglobulinemia (WM) frequently experience anemia and fatigue, which can adversely affect their quality of life. In patients with rituximab-refractory WM, single-agent ibrutinib induced meaningful improvements in patient-reported outcomes.1 In prior reports from the iNNOVATE study, the combination of ibrutinib and rituximab produced higher rates of sustained hemoglobin improvement and meaningful improvements in patient-reported outcomes compared with placebo plus rituximab.2 Hence, ibrutinib is approved in the United States as single-agent therapy and in combination with rituximab for patients with WM. At the ASCO 2019 Annual Meeting, researchers reported detailed patient-reported outcomes analyses from iNNOVATE.

Patients with symptomatic WM requiring therapy were randomized to 420 mg daily of oral ibrutinib and rituximab or placebo and rituximab. In both arms, the rituximab dosing regimen was 375 mg/m2 per week given intravenously at weeks 1 through 4 and at weeks 17 through 20. Patient-reported outcome measures included Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Functional Assessment of Cancer Therapy-Anemia (FACT-An) total score (TS) and anemia subscale score (AS), EQ-5D-5L visual analog scale (EQ-VAS), and utility score.

Of the 75 patients randomized to each arm of the study, the most common reasons for initiating therapy were fatigue (61%), constitutional symptoms (32%), and anemia (32%). Baseline patient-reported outcome scores were comparable in both arms. At a median follow-up of 26.5 months, numerically more patients showed clinically meaningful improvement in FACIT-F (69% vs 57%), as well as FACT-An TS (73% vs 59%) and AS (64% vs 48%), with ibrutinib plus rituximab than with rituximab plus placebo. The median time to improvement in patient-reported outcomes was relatively brief (1-2 months) in both arms. A correlation analysis conducted at week 25 showed that changes in immunoglobulin M (IgM) levels correlated with FACIT-F, FACT-An TS, FACT-An AS, and EQ-VAS for ibrutinib plus rituximab and with FACIT-F and FACT-An TS for rituximab plus placebo. Changes in hemoglobin levels correlated with FACIT-F, FACT-An TS, and FACT-An AS for patients receiving ibrutinib plus rituximab; no meaningful correlations were observed for patients receiving placebo plus rituximab.

Clinical response and improvements in IgM and hemoglobin levels with ibrutinib and rituximab are consistent with prior reports showing clinically meaningful improvement in patient-reported outcomes versus rituximab.

Abstract 8018; Tedeschi A, et al.


References

  1. Trotman J, et al. Patient-reported outcomes with ibrutinib: substudy of iNNOVATE™ for Waldenstrom macroglobulinemia. EHA 2017. Abstract E1246.
  2. Dimopoulos MA, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström’s macroglobulinemia. N Engl J Med. 2018;378:2399-2410.
Related Items
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Comparison of 3 Rituximab-Containing Regimens as Primary Therapy in Patients with WM
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Three-Year Follow-Up of Acalabrutinib and Obinutuzumab in Treatment-Naïve and Relapsed/Refractory CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Evaluation of MRD with Lisocabtagene Maraleucel, a CD19-Directed CAR T Therapy, in Patients with Relapsed/Refractory CLL/SLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Safety and Efficacy of Venetoclax in Combination with Atezolizumab and Obinutuzumab in Richter Transformation of CLL
Conference Correspondent published on June 4, 2019 in ASCO 2019 - Chronic Lymphocytic Leukemia
Last modified: June 7, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME